Search
Showing results for "Childhood interstitial lung disease "
In this study, we investigate the in vivo synergy between romidepsin and cytarabine
Technology-based interventions may provide a relatively low-cost addition to existing therapist-delivered interventions for children with ASD
The ‘Building Social and Emotional Wellbeing Through the Arts Project’ was funded in 2021 by Healthway and supported through a partnership between The Kids Research Institute Australia and Edith Cowan University (ECU).
Infants with KMT2A-rearranged B-cell acute lymphoblastic leukemia (ALL) have a dismal prognosis. Survival outcomes have remained static in recent decades despite treatment intensification and novel therapies are urgently required.
Infants with KMT2A-rearranged B-cell precursor acute lymphoblastic leukemia (ALL) have poor outcomes. There is an urgent need to identify novel agents to improve survival. Proteasome inhibition has emerged as a promising therapeutic strategy for several hematological malignancies. The aim of this study was to determine the preclinical efficacy of the selective proteasome inhibitor carfilzomib, for infants with KMT2A-rearranged ALL.
Growing up in socioeconomic disadvantage increases risk of peer bullying at school. Both socioeconomic status and involvement in bullying are predictive of a range of adverse developmental outcomes. However, neither (a) the mechanisms whereby disadvantage increases bullying risk nor (b) the developmental outcomes for which bullying may mediate disadvantage are clear.
Siblings of children with neurodevelopmental conditions have unique experiences and challenges related to their sibling role. Some develop mental health concerns as measured by self-reported surveys or parent report. Few data are available at the population level, owing to difficulties capturing wide-scale health data for siblings. Data linkage is a technique that can facilitate such research.
The Early Years Partnership is a 10-year (2018-2028) partnership between the WA State Government (Departments of Communities, Health, and Education), Minderoo Foundation and The Kids Research Institute Australia as the evidence and evaluation partner.
Current immunization guidelines recommend one dose of influenza vaccine for children aged ≥9 years and two doses for younger or vaccine-naïve children. However, children receiving chemotherapy have an attenuated immune response. We performed a prospective open-label study in children undergoing treatment for cancer at Perth Children's Hospital, Western Australia, to examine the safety and efficacy of a boosted influenza schedule.
This study sought to determine the social and emotional impact of maternal loss on Aboriginal children and young people using data from the Western...